	US 12,453,747 B2
	Prebiotic formulations for prevention of sepsis and necroenterocolitis induced neurodevelopmental deficiencies
Gail E. Besner, Columbus, OH (US); Michael Bailey, Columbus, OH (US); and Steven Goodman, Columbus, OH (US)
Assigned to Research Institute at Nationwide Children's Hospital, Columbus, OH (US)
Appl. No. 16/961,910
Filed by Research Institute at Nationwide Children's Hospital, Columbus, OH (US)
PCT Filed Jun. 3, 2020, PCT No. PCT/US2020/035976 § 371(c)(1), (2) Date Jul. 13, 2020, PCT Pub. No. WO2020/247536, PCT Pub. Date Dec. 10, 2020.
Claims priority of provisional application 62/856,704, filed on Jun. 3, 2019.
Prior Publication US 2021/0401904 A1, Dec. 30, 2021
Int. Cl. A61K 35/747 (2015.01); A61K 9/16 (2006.01); A61K 35/742 (2015.01); A61K 35/744 (2015.01); A61K 35/745 (2015.01); A61K 47/42 (2017.01); A61P 25/28 (2006.01)

CPC A61K 35/747 (2013.01) [A61K 9/1647 (2013.01); A61K 35/742 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61K 47/42 (2013.01); A61P 25/28 (2018.01)]

27 Claims

1. A method of treating necrotizing enterocolitis (NEC)-induced neurodevelopmental deficiencies in a subject suffering from or has suffered from necrotizing enterocolitis (NEC), comprising administering to the subject an effective amount of a composition comprising a microsphere comprising a biofilm-generating probiotic L. reuteri bacterium and a prebiotic, wherein the bacterium forms a biofilm partially or completely coating the surface of the microsphere, and wherein the prebiotic comprises a nutritional supplementation for the probiotic L. reuteri bacterium.